CA-TRANSPHORM-INC
Transphorm Inc. —the leader in the design and manufacturing of the highest reliability and first JEDEC and AEC-Q101 qualified high voltage gallium nitride (GaN) power semiconductors—today confirmed that customer AES Aircraft Elektro/Elektronik System GmbH has released its first 650 V GaN-based power supplies. Serving the aviation industry, AES supports customers with various products and services ranging from electrical engineering to certification and testing. The company’s newest Switch Mode Power Supplies are currently used by large CS-25 airplane manufacturers (e.g., Airbus A318-A321, A330, A340, A380 and Boeing B767, B787 VIP aircraft) and use Transphorm’s GaN FETs to increase overall system efficiency by more than 10 percent compared to competitive Silicon-based power supply units (PSUs).
The two GaN-based Switch Mode Power Supplies are the PS250X 500 W system and the PS6120 1200 W system . Both products support a 96-130 VAC/360 Hz – 800 Hz input voltage with a 28 VDC continuous power output at 15 amps for the 500 W system and 42 amps for the 1200 W system.
Further, AES certified the PS250X and PS6120 as DO-160 compliant—meeting the more than 25-point stringent Standard of the Radio Technical Commission for Aeronautics (RTCA). This Standard assesses system impact and performance under various external and internal conditions on aircraft—ranging from pressure and temperature to voltage spikes and RF emissions.
The flagship 500 W PS250X is the industry’s first passively cooled power supply at 420 W and deploys Transphorm’s GaN in a single-phase CCM boost power factor correction (PFC) topology. It offers more than 92 percent overall system efficiency at full load, which is more than 10 percent greater than its competition. The system also yields a more than .98 power factor and 200 mVpp nominal at 115 VAC/400 Hz input at full load. All within an end product that is 1.4 kg (~3 lbs).
The 1200 W PS6120 deploys Transphorm’s GaN in a fan-cooled, three-phase CCM boost PFC topology. It offers more than 91.5 percent overall system efficiency at full load, which is 11.5 percent greater than its competition. The PS6120 also yields the same power factor and nominal ripple voltage at 115 VAC/400 Hz input at full load as the PS250X 500 W PSU. All within an end product that is 4.0 kg (~8.8 lbs).
“The aviation industry is working toward reducing climate impact through any means possible,” said Dr. Andreas Hammer, Head of Competence Center Power, AES. “Considering, we sought out Transphorm’s GaN to replace previously used Silicon MOSFETs so that we could provide a more efficient, lighter weight power supply. These supplies have the potential to make a notable impact when considering each aircraft deploys several such PSUs. After only a year of redesign, we were able to offer our customers a better power solution, while also raising the performance bar within our own industry.”
The GaN Selection Process
Interested in the technology’s inherent higher switching frequency, AES reviewed GaN power switch converters from several GaN device semiconductor manufacturers. The company ultimately selected Transphorm’s 650 V GaN technology due primarily to its ease of drivability and designability—specifically because Transphorm’s GaN FETs do not require custom drivers. As a result, system design is simplified while engineers can drive the switches using technology they are already familiar with (i.e., drivers and packages). Other factors affecting AES’ selection included Transphorm’s proven reliability—which is underscored by its GaN platform earning both a JEDEC qualification and AEC-Q101 qualification at 175°C.
“Transphorm designed its GaN devices to enable designers, not challenge them,” said Philip Zuk, VP of Worldwide Technical Marketing and NA Sales, Transphorm, “Our two-switch normally-off GaN devices come in standard packages and require minimal supporting circuitry to drive them, which reduces the overall system size, increases reliability, and simplifies design. It’s crucial to us that our customers can come to market quickly with a product they have confidence in. We’re honored to be AES’ GaN supplier of record and are proud that they appreciate the work we’ve done to bring the benefits of GaN technology to the masses.”
AES’ PS250X and PS6120 power supplies are currently shipping.
About AES
Headquartered in Germany, AES Aircraft Elektro/Elektronik System GmbH is an international company comprised of over 160 highly skilled employees, serving customers in the aviation, space, and maritime industries. AES’ portfolio includes, but is not limited to, aircraft cabins electronics, comprehensive electrical engineering services, electronic design, and certification services.
About Transphorm
Transphorm designs and manufactures the highest performance, highest reliability 650 V and 900 V GaN semiconductors for high-voltage power applications. Holding the largest IP portfolio (1000+ patents), Transphorm produces the industry’s first JEDEC and only AEC-Q101 qualified GaN FETs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191217005252/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
